| Amanda Mullen, MS | |
|
180 Orange Rd, Apt 5b, Montclair, NJ 07042-2644 | |
| (908) 309-6489 | |
| Not Available |
| Full Name | Amanda Mullen |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 180 Orange Rd, Montclair, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316329212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS0049100 (New Jersey) | Primary |
| Provider Name | Pearl Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225630122 PECOS PAC ID: 2466863915 Enrollment ID: O20201204001400 |
News Archive
Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.
Professor Snyder's creativity machine was developed at the Centre for the Mind, a joint venture between The Australian National University and the University of Sydney. The machine transmits harmless magnetic pulses through the brain, temporarily switching part of it off, with the potential to reveal an inner genius
Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens.
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.
Depression affects more than 15 million American adults, or about 6.7 percent of the U.S. population, each year. It is the leading cause of disability for those between the ages of 15 and 44.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Mullen, MS 180 Orange Rd, Apt 5b, Montclair, NJ 07042-2644 Ph: (908) 309-6489 | Amanda Mullen, MS 180 Orange Rd, Apt 5b, Montclair, NJ 07042-2644 Ph: (908) 309-6489 |
News Archive
Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.
Professor Snyder's creativity machine was developed at the Centre for the Mind, a joint venture between The Australian National University and the University of Sydney. The machine transmits harmless magnetic pulses through the brain, temporarily switching part of it off, with the potential to reveal an inner genius
Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens.
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.
Depression affects more than 15 million American adults, or about 6.7 percent of the U.S. population, each year. It is the leading cause of disability for those between the ages of 15 and 44.
› Verified 4 days ago
Ayana Webb, M.A., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 33 Hillside Ave Apt 7, Montclair, NJ 07042 Phone: 732-675-0279 | |
Mary Gagliardotto, MA, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Watchung Plz, Montclair, NJ 07042 Phone: 973-744-0804 | |
Cara Cilento, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 51 Upper Montclair Plz, Montclair, NJ 07043 Phone: 973-519-1989 | |
Brielle Korin Stern, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Watchung Plz, Montclair, NJ 07042 Phone: 973-744-0804 | |
Ciera Marie Iandiorio, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 34 Valley Rd Apt 204, Montclair, NJ 07042 Phone: 973-349-0323 | |
Janel Modoski, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 395 Claremont Ave Apt 2, Montclair, NJ 07042 Phone: 609-529-7194 | |
Eileen Anne Fasanella, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2 Woodmont Rd, Montclair, NJ 07043 Phone: 973-818-2164 |